Physician profile
Eric Daniel Challgren
NPI 1477508893
$47,113.20
in general payments reported to CMS, 2019-2025
43 companies · $17K in 2025
The $17K reported for 2025 was more than what 97% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,989 · 2020: $3,493 · 2021: $2,048 · 2022: $4,486 · 2023: $9,768 · 2024: $7,391 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Consulting Fee: $16K · Travel and Lodging: $854 · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,012.08 |
| Consulting Fee | $15,793.50 |
| Travel and Lodging | $854.49 |
| Education | $438.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15,883.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $6,100.32 | 2022-2025 | Sotyktu |
| Abbvie INC. | $3,688.66 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $2,641.96 | 2019-2025 | Ilumya, Blu-U, Absorica Ld |
| Janssen Biotech, INC. | $1,999.08 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Genentech USA, INC. | $1,765.71 | 2019-2023 | Xolair, Erivedge |
| Regeneron Healthcare Solutions, INC. | $1,657.44 | 2019-2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $1,581.87 | 2025 | Tremfya |
| Leo Pharma INC. | $1,360.84 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Incyte Corporation | $1,350.01 | 2021-2025 | Opzelura, Opzelura |
| Amgen INC. | $1,040.49 | 2019-2025 | Otezla, Otezla, Enbrel |
| Sanofi-Aventis U.S. LLC | $1,016.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $917.76 | 2019-2025 | |
| Lilly USA, LLC | $871.78 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $838.42 | 2019-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $675.06 | 2019-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $658.78 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.25 | 2022-2025 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $318.18 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $314.95 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Dermavant Sciences, INC. | $313.68 | 2022-2024 | Vtama |
| Almirall LLC | $274.17 | 2019-2023 | Seysara |
| Mayne Pharma Commercial LLC | $191.56 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $161.19 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $129.98 | 2019-2025 | Valchlor |
| Dermira, INC. | $112.29 | 2019-2020 | |
| Epi Health, LLC | $109.71 | 2020-2022 | |
| Prugen, INC. Pharmaceuticals | $108.12 | 2019-2020 | |
| Journey Medical Corporation | $87.06 | 2022-2025 | |
| Organon LLC | $69.54 | 2025 | Vtama, Nexplanon |
| Biofrontera INC. | $69.45 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Fresenius Kabi USA, LLC | $65.71 | 2023 | Idacio |
| Aclaris Therapeutics, INC. | $55.27 | 2019 | |
| Celgene Corporation | $52.59 | 2019 | |
| Botanix Sb INC | $50.10 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $48.35 | 2025 | |
| Convatec INC. | $42.99 | 2024 | |
| Organogenesis INC. | $36.45 | 2023 | Puraply |
| Allergan, INC. | $34.89 | 2019-2022 | |
| Strata Skin Sciences, INC. | $17.17 | 2019 | |
| Promius Pharma LLC | $17.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Dusa Pharmaceuticals, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Challgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.